𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

✍ Scribed by Hochhaus, A; Kreil, S; Corbin, A S; La Rosée, P; Müller, M C; Lahaye, T; Hanfstein, B; Schoch, C; Cross, N C P; Berger, U

Book ID
110055297
Publisher
Nature Publishing Group
Year
2002
Tongue
English
Weight
177 KB
Volume
16
Category
Article
ISSN
0887-6924

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Chronic myelogenous leukemia in T cell l
Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy
✍ Ehab Atallah; Moshe Talpaz; Susan O'brien; Mary Beth Rios; Jie Qiang Guo; Ralph 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

## Abstract ## BACKGROUND A T cell lymphoid blastic phase of chronic myelogenous leukemia (CML) is a rare occurrence, with only a few reported cases worldwide. Standard therapy for such patients is undetermined. Imatinib mesylate, a Bcr‐Abl tyrosine kinase inhibitor, has shown activity in CML. ##

Changes associated with the development
Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein
✍ Barbara Scappini; Simona Gatto; Francesco Onida; Clara Ricci; Vladimir Divoky; W 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 279 KB 👁 1 views

## Abstract ## BACKGROUND Although various mechanisms have been recognized as being associated with the development of resistance to imatinib mesylate in vitro and in clinical situations, their relative significance and contributions remain poorly understood, as is the sequence of events leading t